Groundbreaking Leukemia Drug Starts at Ohio State, Now Used Worldwide

A breakthrough drug developed at The James could change the future of treatment for many leukemia patients.

An OSUCCC – James study showed the new treatment, ibrutinib, significantly slows the progression of chronic lymphocytic leukemia (CLL) in older patients. The findings could make CLL more manageable in patients across the world.

“Our results establish that ibrutinib should be a standard of care for older patients with CLL—it is more effective than the best available chemoimmunotherapy regimen,” says lead study author Jennifer Woyach, MD.